p53 mutations, asset or liability for cancer chemotherapy?;Les mutations de p53, un atout ou un inconvenient pour la chimiotherapie?

Bulletin du Cancer

Volumn 84, Issue 7, 1997, Pages 741-746

  Jacquemin Sablon, Alain ^a  

^a Institut GustaveRoussy   (France)

Author keywords

Cancer cells; Chemotherapy; P53

Indexed keywords

PROTEIN P53;

APOPTOSIS; CANCER CHEMOTHERAPY; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CHEMOSENSITIVITY; DNA DAMAGE; GENE MUTATION; HUMAN; REVIEW;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL DIVISION; DNA DAMAGE; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; G1 PHASE; GENE EXPRESSION REGULATION; GENES, P53; HUMANS; MUTATION; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030747597     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Dive C, Hickmon JA. Drug-target interactions : only the first step in the commitment to a programmed cell death ? Br J Cancer 1991 ; 64 : 192-6.
2. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992 ; 69 : 119-28.
3. Fanidi A, Harrington EA, Evan GI. Cooperative interaction between c-myc and bcl-2 oncogenes. Nature 1992 ; 359 : 554-6.
4. Lotem J, Sachs L. Regulation by bcl-2, c-myc, and p53, of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth Diff 1993 ; 4 : 41-7.
5. Lowe SC, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993 ; 74 : 957-67.
6. Lane DP. p53, guardian of the genome. Nature 1992 ; 358 : 15-6.
7. Ko U, Prives C. p53 : puzzle and paradigm. Genes & Dev 1996 ; 10 : 1054-72.
8. Donehower LA, Bradley A. The tumor suppressor p53. Biochim Biophys Acta 1993 ; 1155 : 181-205.
9. Nelson WG, Kastan MB. DNA strand breaks : the DNA template alterations that trigger p53 dependent DNA damage response pathway. Mol Cell Biol 1994 ; 14 : 1815-23.
10. EI-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993 ; 75 : 817-25.
11. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip 1 is a potent inhibitor of G1 cyclindependent kinases. Cell 1993 ; 75 : 805-16.
12. Agarwal ML, Agarwal A, Taylor WR, Stark GR. p53 controls both the G2/M and the G1 cell cycle check points and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA 1995 ; 92 : 8493-7.
13. Dulic V, Kaufman WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation induced G1 arrest. Cell 1994 ; 76 : 1013-23.
14. Kastan MB, Zhan O, EI-Deiry WS, Carrier F, Jacks T, Walsh WV, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telengiectasia. Cell 1992 ; 71 : 587-97.
15. Smith ML, Chen IT, Zhan Q, Bae I, Chen C, Gilmer TM, et al. Interaction of p53-regulated protein gadd-45 with proliferating cell nuclear antigen. Science 1994 ; 266 : 1376-80.
16. Wang XW, Yeh H, Schaeffer L, Roy R, Moncollin V, Egly J, et al. p53 modulation of TFIIH-associated nucleotide excision repair activity. Nafure Genetics 1995 ; 10 : 188-95.
17. Oliner JD, Pietenpol JA, Thiagaligam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature 1993 ; 362 : 857-60.
18. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997 ; 387 : 296-9.
19. Kubbutat MHG, Jones SJ, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997 ; 387 : 299-303.
20. Miyashita T, Reed JC. Tumor suppresseur p53 is a direct transcriptional activator of the human box gene. Cell 1995 ; 80 : 293-9.
21. White E. Life, death, and the pursuit of apoptosis. Genes & Dev 1996 ; 10 : 1-15.
22. Lowe SW, Bodis S, McClatchey AM, Remington L, Ruley HE, Fischer DA, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994 ; 266 : 807-10.
23. Skladanowski A, Larsen A. Expression of wild-type p53 increases etoposide cytotoxicity in Ml myeloid leukemia cells by facilitated G2 to M transition : implications for gene therapy. Cancer Res 1997 ; 57 : 818-23.
24. Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC, Young LS. The control of apoptosis and drug resistance in ovarian cancer : influence of p53 and Bcl-2. Oncogene 1995 ; 11 : 1217-28.
25. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, et al. Association between cisplatin resistance and mutation of p53 gene and reduced Box expression in ovarian carcinoma cell systems. Cancer Res 1996 ; 56 : 556-62.
26. Fajac A, Da Silva J, Ahomadegbe JC, Rateau J-G, Bernaudin J-F, Riou G, Bénard J. Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line. Int J Cancer 1996 ; 68 : 67-74.
27. Fan S, EI-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, et al. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 1994 ; 54 : 5824-30.
28. Chresta CM, Masters JR, Hickman JA. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res 1996 ; 56 : 1834-41.
29. Brachman DG, Becketl M, Graves D, Haraf D, Vokes E, Weichselbaum RR. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res 1993 ; 53 : 3667-9.
30. Biard DSF, Martin M, Le Rhun Y, Duthu A, Lefaix JL, May E, May P. Concomitant p53 gene mutation and increased radiosensitivity in rat lung embryo epithelial cells during neoplastic development. Cancer Res 1994 ; 54 : 3361-4.
31. Hawkins DS, Demers GW, Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 1996 ; 56 : 892-8.
32. Cote RJ, Esrig D, Groshen S, Jones PA, Skinner DG. p53 and treatment of bladder cancer [correspondance]. Nature 1997 ; 385 : 123-5.
33. Haupt Y, Barak Y, Oren M. Cell type-specific inhibition of p53 mediated apoptosis by mdm2. EMBO J 1996 ; 15 : 1596-606.
34. Larsen CJ. box, un gène régulateur de l'apoptose, se comporte également comme un gène suppresseur de tumeur. Bull Cancer 1997 ; 84 (4) : 454.
35. Rampino NH, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, Perucho M. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite rnutator phenotype. Science 1997 ; 275 : 967-9.
36. Ségal-Bendirdjian E, Jacquemin-Sablon A. Cisplatin resistance in a murine leukemia cell line is associated with a defective apoptotic process. Exp Cell Res 1995 ; 218 : 201-12.
37. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, et al. Gain of function mutations in p53. Nature Genet 1993 ; 4 : 42-6.
38. Chin KV, Ueda K, Pastan I, Gottesman MM. Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science 1992 ; 255 : 459-62.
39. Wallach D. Cell death induction by TNF : a matter of delf control. Trends Biochem Sci 1997 ; 22 : 107-9.